ARCT

9.11

3.95% -0.375

Handel nachbörslich: 9.55 0.44 +4.83%

Arcturus Therapeutics Holdings Inc (ARCT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$9.485

Offen:

$9.12

24-Stunden-Volumen:

579.45K

Relative Volume:

1.43

Marktkapitalisierung:

$247.06M

Einnahmen:

$157.75M

Nettoeinkommen (Verlust:

$-29.73M

KGV:

-7.8534

EPS:

-1.16

Netto-Cashflow:

$-21.00M

1W Leistung:

-21.33%

1M Leistung:

-41.19%

6M Leistung:

-61.85%

1J Leistung:

-70.23%

1-Tages-Spanne:

$8.695

$9.35

1-Wochen-Bereich:

$8.695

$11.24

52-Wochen-Spanne:

$8.695

$45.00

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Firmenname

Arcturus Therapeutics Holdings Inc

Sektor

Healthcare (1171)

Branche

Biotechnology (673)

Telefon

(858) 900-2660

Adresse

10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA

Mitarbeiter

176

Twitter

@ArcturusRx

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

ARCT's Discussions on Twitter

Vergleichen Sie ARCT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ARCT Arcturus Therapeutics Holdings Inc	9.11	247.06M	157.75M	-29.73M	-21.00M	-1.16
VRTX Vertex Pharmaceuticals Inc	474.62	121.88B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	573.45	62.69B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	555.11	33.86B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.74	30.51B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.51	25.69B	3.81B	-644.79M	-669.77M	-6.24

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-01-28	Eingeleitet	BTIG Research	Buy
2024-08-12	Eingeleitet	Leerink Partners	Outperform
2023-12-13	Eingeleitet	Canaccord Genuity	Buy
2023-07-24	Eingeleitet	William Blair	Outperform
2023-05-11	Hochstufung	H.C. Wainwright	Neutral → Buy
2022-11-14	Fortgesetzt	Wells Fargo	Overweight
2022-11-10	Herabstufung	Robert W. Baird	Neutral → Underperform
2022-11-03	Hochstufung	Citigroup	Neutral → Buy
2022-11-02	Hochstufung	Barclays	Underweight → Equal Weight
2022-08-10	Herabstufung	Raymond James	Mkt Perform → Underperform
2022-07-19	Fortgesetzt	Cantor Fitzgerald	Overweight
2022-05-11	Hochstufung	Robert W. Baird	Underperform → Neutral
2022-04-21	Herabstufung	Citigroup	Buy → Neutral
2022-01-31	Hochstufung	Raymond James	Underperform → Mkt Perform
2021-08-12	Herabstufung	Raymond James	Mkt Perform → Underperform
2021-08-11	Herabstufung	Goldman	Neutral → Sell
2021-08-10	Herabstufung	Robert W. Baird	Neutral → Underperform
2021-07-02	Eingeleitet	Cantor Fitzgerald	Overweight
2021-06-25	Fortgesetzt	Goldman	Neutral
2021-06-21	Herabstufung	Barclays	Equal Weight → Underweight
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-02-17	Herabstufung	B. Riley Securities	Neutral → Sell
2021-01-19	Herabstufung	B. Riley Securities	Buy → Neutral
2021-01-15	Herabstufung	B. Riley Securities	Buy → Neutral
2021-01-07	Eingeleitet	Wells Fargo	Overweight
2020-12-29	Herabstufung	Barclays	Overweight → Equal Weight
2020-12-29	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-12-29	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-12-29	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-12-23	Herabstufung	ROTH Capital	Buy → Sell
2020-12-08	Bestätigt	B. Riley Securities	Buy
2020-12-07	Bestätigt	B. Riley Securities	Buy
2020-10-26	Eingeleitet	Barclays	Overweight
2020-10-06	Eingeleitet	Citigroup	Buy
2020-08-26	Eingeleitet	Piper Sandler	Overweight
2020-07-30	Fortgesetzt	ROTH Capital	Buy
2020-07-16	Eingeleitet	Raymond James	Outperform
2020-07-13	Eingeleitet	B. Riley FBR	Buy
2020-06-09	Herabstufung	WBB Securities	Buy → Hold
2020-02-11	Eingeleitet	Robert W. Baird	Outperform
2020-02-07	Eingeleitet	Guggenheim	Buy
2020-02-06	Eingeleitet	Guggenheim	Buy
2019-04-05	Eingeleitet	H.C. Wainwright	Buy
2018-09-20	Hochstufung	WBB Securities	Buy → Strong Buy
2018-01-22	Eingeleitet	Chardan Capital Markets	Buy

Alle ansehen

Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten

Mar 26, 2025

(ARCT) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Mar 26, 2025

Mar 24, 2025

Bank of New York Mellon Corp Sells 22,024 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Mar 24, 2025

Mar 20, 2025

Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey

Mar 20, 2025

Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet - simplywall.st

Mar 20, 2025

Mar 18, 2025

Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis - MSN

Mar 18, 2025

Mar 17, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $61.40 Average PT from Analysts - Defense World

Mar 13, 2025

Mar 12, 2025

Arcturus Therapeutics at Leerink’s Conference: mRNA Innovations and Strategic Plans - Investing.com UK

Mar 12, 2025

Despite Revenue Setback, Arcturus Therapeutics (ARCT) Vaccine Breakthroughs Fuel Optimism - markets.businessinsider.com

Mar 12, 2025

Mar 11, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Given New $68.00 Price Target at Canaccord Genuity Group - Defense World

Mar 11, 2025

Mar 09, 2025

Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results - Simply Wall St

Mar 09, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

Mar 09, 2025

HC Wainwright Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $60.00 - Defense World

Mar 09, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Earns Overweight Rating from Cantor Fitzgerald - Defense World

Mar 09, 2025

Mar 08, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025

Mar 07, 2025

Arcturus Therapeutics stock hits 52-week low at $14.3 By Investing.com - Investing.com Australia

Mar 07, 2025

Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock - Benzinga

Mar 07, 2025

Arcturus Therapeutics stock hits 52-week low at $14.3 - Investing.com India

Mar 07, 2025

Earnings call transcript: Arcturus Therapeutics Q4 2024 misses estimates By Investing.com - Investing.com South Africa

Mar 07, 2025

Arcturus Therapeutics Reports Q4 2024 Earnings: EPS of ($1.11) M - GuruFocus.com

Mar 07, 2025